Purple Biotech Ltd. · TASE:PPBT
Purple Biotech — Kitov Pharma — 18th MIXiii-Biomed Conference and Exhibition 2019
16 slides from Purple Biotech's conference presentation, May 16, 2019
Slide 1: NT219 - Overcoming Cancer Drug Resistance
Thank you Kitov Pharma NT219 - Overcoming Cancer Drug Resistance Isaac Israel - Chief Executive Officer MIXiii - Biomed - May 16 th , 2019
Slide 2: Forward-Looking Statements and Kitov's Safe Harbor Statement
Forward - Looking Statements and Kitov ’ s Safe Harbor Statement Ϯ This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looking statements within the meaning of the safe harbor provisions of
Slide 3: About Kitov
About Kitov • Publicly traded on TASE 2013 ; IPO on NASDAQ in November 2015 • Tickers: KTOV (ADSs); KTOVW (Warrants) • Cash on hand (as of January 2019 ): Ε $ 13 M + $ 3.5 M of investment pending closing of CM - 24 transaction • Market Cap: ~$ 31 M * • ~ 35 % of the shares held by blue - chip, insti
Slide 4: Commercial and Development Pipeline
ϰ Program Indication Preclinical Phase 1 Phase 2 Phase 3 Market Partners Consensi ™ Osteoarthritis Pain and Hypertension Commercial partners: Coeptis Pharmaceuticals - U.S. CSBio - China Kuhnil Pharmaceuticals - S . Korea CM - 24 Non - Small Cell Lung Cancer (combination with nivolumab ) Bristol - M
Slide 5: ϱ
ϱ NT - 219
Slide 6: Targeting cancer drug resistance
Targeting cancer drug resistance • Many cancer patients either don ’ t respond to single agent therapies or relapse quickly after initially responding • Overcoming cancer drug resistance (intrinsic and acquired) is a major unmet need in cancer treatment • Effective combination therapies that act syn
Slide 7: IRS1/2 and STAT3 key signal transducers in drug resistance
Adapted from Clinics vol. 73 supl. 1 2018 IRS 1 / 2 : IRS 1 / 2 and STAT 3 Key Signal Transducers activated as a feedback response to anti - cancer drugs, leading to drug resistance ϳ STAT 3 : • Part of the IGFR complex • Phosphorylated on tyrosine residues and triggers activation of PI 3 K/AKT and
Slide 8: NT219 is a First-in-class Dual Inhibitor of STAT3 and IRS1/2
NT - 219 is a First - in - class Dual Inhibitor of STAT 3 and IRS 1 / 2 Blocking both pathways is required to overcome resistance and to re - sensitize tumors to anti - cancer therapies ϴ Feedback ONCOPROTEIN DRUG MEK / ERK TUMOR PROREGRESSION STAT 3 TUMOR SURVIVAL IRS TUMOR SURVIVAL AKT ONCOPROTEIN
Slide 9: Preclinical Data: Prevents Acquired Resistance to Erlotinib in Head and Neck Cancer
ϵ NT - 219 Preclinical Data Prevents Acquired Resistance to Erlotinib in Head and Neck Cancer Ͳ PDX Model
Slide 10: Preclinical Data: Reverses Acquired Resistance to Erlotinib in Head and Neck Cancer
ϭϬ NT - 219 + erlotinib NT - 219 Preclinical Data Reverses Acquired Resistance to Erlotinib in Head and Neck Cancer Ͳ PDX Model
Slide 11: Preclinical Data: Delays Tumor Recurrence with Cetuximab in Head and Neck Cancer
ϭϭ NT - 219 Preclinical Data Delays Tumor Recurrence with Cetuximab in Head and Neck Cancer PDX Model
Slide 12: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) ϭϮ • EGFR and PD(L) - 1 are the only clinically validated targets in SCCHN • Cetuximab inhibits EGFR signaling and promotes ADCC • Activation of STAT 3 and IRS - to - AKT contributes to resistance to cetuximab in SCCHN * Gl
Slide 13: Clinical Development Plan
NT - 219 Clinical Development Plan • A Phase 1 / 2 open label multi center study of NT - 219 in combination with cetuximab in patients with recurrent or metastatic SCCHN 1. Dose escalation of NT - 219 in combination with cetuximab 2. Expansion cohort - NT - 219 + cetuximab • Primary endpoint : Evalu
Slide 14: Summary
NT - 219 Summary ϭϰ • Cancer drug resistance (intrinsic and acquired) is a major unmet need in cancer treatment • NT - 219 is a first - in - class dual inhibitor of STAT 3 and IRS 1 / 2 • Broad efficacy demonstrated in various patient - derived xenograft (PDX) SCCHN models in combination with cetuxi
Slide 15: About Kitov
About Kitov • Publicly traded on TASE 2013 ; IPO on NASDAQ in November 2015 • Tickers: KTOV (ADSs); KTOVW (Warrants) • Cash on hand (as of January 2019 ): Ε $ 13 M + $ 3.5 M of investment pending closing of CM - 24 transaction • Market Cap: ~$ 31 M * • ~ 35 % of the shares held by blue - chip, insti
Slide 16: Thank you
Thank you Our mission is to provide cancer patients with first - in - class therapies to overcome tumor drug resistance , enhance treatment response and slow tumor progression
Kitov Pharma — 18th MIXiii-Biomed Conference and Exhibition 2019 on 6ix